Related Experiment Videos
Aspirin reduces endothelial cell senescence.
Stefanie M Bode-Böger1, Jens Martens-Lobenhoffer, Michael Täger
1Institute of Clinical Pharmacology, University Hospital, Otto-von-Guericke University, Germany. stefanie.bode-boeger@medizin.uni-magdeburg.de
Biochemical and Biophysical Research Communications
|July 26, 2005
Summary
Aspirin delays endothelial cell aging by maintaining nitric oxide (NO) levels. This research shows aspirin inhibits senescence, offering a potential therapeutic strategy against age-related NO decline.
Area of Science:
- Cellular senescence
- Endothelial cell biology
- Aging research
Background:
- Replicative senescence is a hallmark of cellular aging.
- Endothelial cell aging is linked to various age-related diseases.
- Nitric oxide (NO) bioavailability decreases with age, contributing to endothelial dysfunction.
Purpose of the Study:
- To investigate the effect of aspirin on the onset of replicative senescence in endothelial cells.
- To elucidate the molecular mechanisms underlying aspirin's impact on endothelial aging.
- To determine if aspirin's anti-aging effects are specific and mediated by nitric oxide pathways.
Main Methods:
- Endothelial cells were cultured to replicative senescence (cumulative population doublings 40).
- Cells were treated with aspirin, other NSAIDs (ibuprofen, acetaminophen), or NO synthase inhibitors (l-NAME).
- Assays were performed to measure senescence-associated beta-galactosidase activity, telomerase activity, reactive oxygen species (ROS), nitric oxide (NO), cGMP, asymmetric dimethylarginine (ADMA) levels, and dimethylarginine dimethylaminohydrolase (DDAH) activity.
Main Results:
- Aspirin significantly delayed the onset of endothelial senescence, evidenced by reduced beta-galactosidase activity and increased telomerase activity.
- Aspirin decreased ROS levels and increased NO and cGMP levels.
- Aspirin reduced ADMA levels and upregulated DDAH activity, while other NSAIDs did not show these effects.
- The NO synthase inhibitor l-NAME blocked aspirin's delay of senescence, confirming the role of NO.
Conclusions:
- Aspirin delays endothelial cell senescence by preventing the age-related decrease in nitric oxide (NO) formation.
- The mechanism involves reducing ADMA levels and enhancing DDAH activity, thereby increasing NO bioavailability.
- These findings suggest aspirin as a potential therapeutic agent to counteract aging-induced NO inhibition and promote vascular health.